Despite there being so many holders here, cheering on the sudden price rise and saying approval is inevitable, not a single one has been able to answer the following simple question:
- If MSB received 2 CRLs for the last submissions, what tangible difference is there for this submission that makes you certain it will be accepted?
There's no new clinical data from trials - that's a fact.
The FDA explicitly said it wants new clinical data - also a fact.
So what do we have this time? Other than Si's optimism and his platitudes full of caveats like "may, should, suspect, etc".
Should be easy to answer. Please prove me wrong.
MSB Price at posting:
$1.09 Sentiment: Sell Disclosure: Not Held
(20min delay)